AP2498A - Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol - Google Patents

Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Info

Publication number
AP2498A
AP2498A AP2009004870A AP2009004870A AP2498A AP 2498 A AP2498 A AP 2498A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2498 A AP2498 A AP 2498A
Authority
AP
ARIPO
Prior art keywords
alpha
beta
quinolineethanol
naphthalenyl
dimethylamino
Prior art date
Application number
AP2009004870A
Other languages
English (en)
Other versions
AP2009004870A0 (en
Inventor
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2498(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP2009004870A0 publication Critical patent/AP2009004870A0/xx
Application granted granted Critical
Publication of AP2498A publication Critical patent/AP2498A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2009004870A 2006-12-05 2007-12-03 Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol AP2498A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (2)

Publication Number Publication Date
AP2009004870A0 AP2009004870A0 (en) 2009-06-30
AP2498A true AP2498A (en) 2012-10-19

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004870A AP2498A (en) 2006-12-05 2007-12-03 Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Country Status (34)

Country Link
US (1) US8546428B2 (ar)
EP (1) EP2086940B1 (ar)
JP (2) JP2010511663A (ar)
KR (1) KR101514700B1 (ar)
CN (2) CN101547904A (ar)
AP (1) AP2498A (ar)
AR (1) AR064149A1 (ar)
AU (1) AU2007328945B2 (ar)
BR (1) BRPI0719693A2 (ar)
CA (1) CA2668512C (ar)
CL (1) CL2007003472A1 (ar)
CY (1) CY1113594T1 (ar)
DK (1) DK2086940T3 (ar)
EA (1) EA017091B9 (ar)
ES (1) ES2387923T3 (ar)
HK (1) HK1214513A1 (ar)
HR (1) HRP20120639T1 (ar)
IL (1) IL199077A (ar)
JO (1) JO2973B1 (ar)
ME (1) ME01456B (ar)
MX (1) MX2009005909A (ar)
MY (1) MY148844A (ar)
NO (1) NO342773B1 (ar)
NZ (1) NZ576485A (ar)
PE (1) PE20081350A1 (ar)
PL (1) PL2086940T3 (ar)
PT (1) PT2086940E (ar)
RS (1) RS52408B (ar)
SI (1) SI2086940T1 (ar)
TW (1) TWI417098B (ar)
UA (1) UA97813C2 (ar)
UY (1) UY30762A1 (ar)
WO (1) WO2008068231A1 (ar)
ZA (1) ZA200903907B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
HK1243644A1 (zh) * 2015-01-27 2018-07-20 Janssen Pharmaceutica Nv 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
PL3971177T3 (pl) * 2016-07-20 2024-10-28 Novartis Ag Pochodne aminopirydyny i ich zastosowanie jako selektywne inhibitory alk-2
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
EP0936866A4 (en) 1996-10-28 2001-04-11 Dept Of The Army Us Government Compounds, compositions and methods for treating antibiotic-resistant infections
YU42397A (sh) * 1996-10-30 2000-10-30 Eli Lilly And Company Korišćenje raloksifena za pripremu leka
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AP2487A (en) * 2004-09-02 2012-10-03 Janssen Pharmaceutica Nv Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY, 14 May 2005 (2005-05-14), XP002433954, accession no. 845533-86-0, abstract *

Also Published As

Publication number Publication date
CA2668512A1 (en) 2008-06-12
JP2010511663A (ja) 2010-04-15
MY148844A (en) 2013-06-14
NO20092535L (no) 2009-08-06
PL2086940T3 (pl) 2012-10-31
BRPI0719693A2 (pt) 2013-12-24
WO2008068231A1 (en) 2008-06-12
US20100028428A1 (en) 2010-02-04
ZA200903907B (en) 2013-08-28
ES2387923T3 (es) 2012-10-04
EP2086940B1 (en) 2012-05-16
IL199077A (en) 2016-09-29
NO342773B1 (no) 2018-08-06
US8546428B2 (en) 2013-10-01
KR101514700B1 (ko) 2015-04-24
KR20090087020A (ko) 2009-08-14
RS52408B (sr) 2013-02-28
AU2007328945A1 (en) 2008-06-12
EA017091B9 (ru) 2014-10-30
CN105012303A (zh) 2015-11-04
PE20081350A1 (es) 2008-09-18
HK1214513A1 (zh) 2016-07-29
JP2015028049A (ja) 2015-02-12
UA97813C2 (uk) 2012-03-26
JP5894239B2 (ja) 2016-03-23
HRP20120639T1 (hr) 2012-08-31
CY1113594T1 (el) 2016-06-22
MX2009005909A (es) 2009-06-16
AP2009004870A0 (en) 2009-06-30
CA2668512C (en) 2015-03-24
UY30762A1 (es) 2008-07-03
TW200838527A (en) 2008-10-01
SI2086940T1 (sl) 2012-09-28
ME01456B (me) 2014-04-20
AU2007328945B2 (en) 2014-04-03
TWI417098B (zh) 2013-12-01
DK2086940T3 (da) 2012-08-20
CL2007003472A1 (es) 2008-08-22
JO2973B1 (ar) 2016-03-15
AR064149A1 (es) 2009-03-18
CN101547904A (zh) 2009-09-30
EA017091B1 (ru) 2012-09-28
EA200970532A1 (ru) 2009-10-30
NZ576485A (en) 2012-01-12
PT2086940E (pt) 2012-08-09
EP2086940A1 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
AP2498A (en) Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
EP2046259A4 (en) PATIENTS LIEGE
GB0610680D0 (en) Therapeutic compounds
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
IL193102A0 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
GB2458228B (en) External preparation for skin
ZA200900004B (en) Therapeutic compounds
GB0603041D0 (en) Therapeutic compounds
IL187715A0 (en) Use of phenylsemicarbazones for seed treatment
GB0606663D0 (en) Therapeutic compounds
GB0612971D0 (en) Therapeutic compounds
IL205752A0 (en) Octahydroquinolizines for antidiabetic treatment
GB0625349D0 (en) Therapeutic compounds
GB0625345D0 (en) Therapeutic compounds
GB0605573D0 (en) Therapeutic Compounds
ZA200800393B (en) Use of phenylsemicarbazones for seed treatment
ZA200903242B (en) Treatment for multiple myeloma
GB0608269D0 (en) Therapeutic compounds
GB2439923B (en) Therapeutic compounds
ITMI20060760A1 (it) Procedimento per il trattamento di tessuti
AU312983S (en) Headgear for patient interface
AU312984S (en) Headgear for patient interface
GB0610670D0 (en) Therapeutic compounds
GB0614082D0 (en) Therapeutic compounds
GB0604049D0 (en) Therapeutic compounds